AFP is currently the serum marker most widely used for HCC screening, diagnosis, and the evaluation of therapeutic efficacy; however, more than 35% of HCC patients do not present elevated serum AFP levels even in the late stages [26]. This evidence concerns the gene AFP and hepatocellular carcinoma.